All In Biotech

Drug Trial Radar · NCT07862621

A Clinical Trial of MK-6916 With Midazolam and Rosuvastatin in Healthy Participants (MK-6916-012)

A 2-period Study to Evaluate the Effects of Multiple Oral Doses of MK-6916 on the Single-dose Pharmacokinetics of Midazolam and Rosuvastatin

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Feb 9, 2027

Study completion Feb 19, 2027

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Researchers are looking for new treatments for pain. The goal of this trial is to learn if MK-6916 changes what happens to the midazolam and rosuvastatin in healthy participants' bodies. Researchers will compare the amount of midazolam and rosuvastatin in a participant's body over time when they are given with and without MK-6916.

Conditions

  • Healthy

Interventions

  • MidazolamDrug

    Administered orally on Day 1 of Period 1 and on Days 2 and 14 of Period 2.

  • RosuvastatinDrug

    Administered orally on Day 1 of Period 1 and Day 14 of Period 2.

  • MK-6916Drug

    Administered orally once every 12 hours on Days 1 through 18 in Period 2.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Period 1: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MidazolamTime frame: Predose and at designated timepoints up to approximately 24 hours
  2. Period 2: AUC0-inf of MidazolamTime frame: Predose and at designated timepoints up to approximately Day 15
  3. Period 1: AUC0-inf of RosuvastatinTime frame: Predose and at designated timepoints up to approximately 96 hours
  4. Period 2: AUC0-inf of RosuvastatinTime frame: Predose and at designated timepoints up to approximately Day 19

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.